Bank of America to Open More Than 150 Additional Branches By 2027
Bank of America will open more than 150 new branches in 60 markets across the United States by the end of 2027, it said in a May 13
Of those, 40 are set to open this year, with 70 scheduled for 2026, the bank said, adding that more than $5 billion has been invested since 2016 in opening new centers and renovating existing ones.
A new flagship financial center recently opened in 2 Bryant Park in New York City. In Idaho, the bank will open four financial centers to serve customers in Boise—the first of which is set to open on June 9 in Nampa, roughly 20 miles west of Boise.
'Our continued investment in our financial center network reflects our commitment to meeting our clients where they are and how they want to bank with us,' said Holly O'Neill, president of consumer, retail, and preferred at the institution.
Bank of America offers banking access to almost 250 million people in 200 markets in the United States, representing roughly 82 percent of the American population, the bank's website says.
Almost 30 percent of the institution's branches are in low- and moderate-income communities.
Related Stories
5/13/2025
5/14/2025
The expansion plan comes as Bank of America reported its first-quarter financial results last month, announcing a net income of $7.4 billion, up from $6.7 billion in the same quarter in 2024. Total revenues came in at $27.4 billion, up from $25.8 billion.
In the consumer banking segment, the company reported opening 250,000 net new consumer checking accounts, its 25th consecutive quarterly growth.
In an
'Trading revenues hit new highs, and wealth management showed strong asset growth,' he said. 'Digital banking activity also continued to rise. Deposits increased for the seventh straight quarter, reflecting continued customer confidence. Shareholder returns were also robust.'
Koimisis highlighted an area of concern: investment banking. Banking fees have slightly fallen in the segment, he said, adding that this likely reflects a slowdown in deal activity amid geopolitical tensions and global uncertainty.
US Banking Sector in 2025
Multiple banking institutions have announced expansion plans over the past year.
In November, PNC Bank
In February 2024, Chase
In a Feb. 3
It forecasted that banks will benefit from several factors, such as eased regulations and accelerated mergers and acquisitions (M&A).
'Regulatory agencies under the Biden administration proved to be a headwind as bank M&A (similar to M&A in other sectors) saw more scrutiny and a prolonged approval process. As a result, bank management teams took a cautious approach to strategic transactions,' the post said.
However, 'postelection, management teams have been much more constructive in their dialogue. The new administration looks to be much more business-friendly. As a result, we expect to see some regulatory relief for the banking industry.'
A Jan. 5
The banking industry is expected to generate a return on common equity of 10.5 to 11.5 percent in 2025, it said. Return on equity is a measure of a company's financial performance. In 2024, the industry's return on equity was estimated at 11 to 11.5 percent.
Panos Mourdoukoutas contributed to the report.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
6 minutes ago
- Bloomberg
Bessent Looks to Revamp Currency Monitoring After Damage Done
I'm Chris Anstey, an economics editor in Boston. Today we're looking at the US Treasury's semiannual foreign-exchange report. Send us feedback and tips to ecodaily@ And if you aren't yet signed up to receive this newsletter, you can do so here. The first US Treasury semiannual assessment of American trading partners' exchange-rate policies since Trump returned to the White House read, in substance, much the same as the last one under President Joe Biden.
Associated Press
7 minutes ago
- Associated Press
Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer
– This submission is supported by the pivotal Phase 3 VERITAC-2 clinical trial, results of which were recently presented at the 2025 American Society for Clinical Oncology Annual Meeting and published in The New England Journal of Medicine – – VERITAC-2 data support vepdegestrant as a potential treatment option in patients with ESR1m ER+/HER2- advanced or metastatic breast cancer – NEW HAVEN, Conn., June 06, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) with its partner Pfizer Inc. (NYSE: PFE), for vepdegestrant for the treatment of patients with ER-positive (ER+)/human epidermal growth factor receptor 2 (HER2)-negative (ER+/HER2-) ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. This submission is based on results from VERITAC-2 (NCT05654623), a global, randomized Phase 3 trial evaluating vepdegestrant versus fulvestrant. 'This milestone comes after an exciting presentation at the American Society of Clinical Oncology's annual meeting,' said John Houston, Ph.D., Chairperson, Chief Executive Officer and President at Arvinas. 'We look forward to the NDA review and to the first ever FDA-approved PROTAC ER degrader potentially being available to patients who could benefit from a much needed, new treatment option.' Vepdegestrant is being jointly developed by Arvinas and Pfizer for the treatment of patients with advanced or metastatic ER+/HER2- breast cancer and was granted fast track designation as a monotherapy by the FDA. Results from the VERITAC-2 study were recently presented in a late-breaking oral presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting and were selected for the ASCO press briefing and for Best of ASCO. Detailed results were also simultaneously published in the New England Journal of Medicine. About the VERITAC-2 Clinical Trial The Phase 3 VERITAC-2 clinical trial ( NCT05654623 ) is a global, randomized trial evaluating the efficacy and safety of vepdegestrant (ARV-471) as a monotherapy compared to fulvestrant in patients with ER+/HER2- advanced or metastatic breast cancer. The trial enrolled 624 patients at sites in 25 countries who had previously received treatment with a CDK4/6 inhibitor plus endocrine therapy. Patients were randomized 1:1 to receive either vepdegestrant once daily, orally on a 28-day continuous dosing schedule, or fulvestrant, administered intramuscularly on Days 1 and 15 of Cycle 1 and then on Day 1 of each 28-day cycle starting from Day 1 of Cycle 2. In the trial, 43% of patients (n=270) had ESR1 mutations detected. The primary endpoint was progression-free survival (PFS) in the ESR1-mutation and intent-to-treat populations as determined by blinded independent central review. Overall survival is the key secondary endpoint. About Vepdegestrant Vepdegestrant is an investigational, orally bioavailable PROTAC (PROteolysis TArgeting Chimera) protein degrader designed to specifically target and degrade the estrogen receptor (ER). Vepdegestrant is being developed as a potential monotherapy for ER+/HER2- advanced or metastatic breast cancer with estrogen receptor 1 (ESR1) mutations in the second line-plus setting. In July 2021, Arvinas announced a global collaboration with Pfizer for the co-development and co-commercialization of vepdegestrant; Arvinas and Pfizer will share worldwide development costs, commercialization expenses, and profits. The U.S. Food and Drug Administration (FDA) has granted vepdegestrant Fast Track designation as a monotherapy in the treatment of adults with ER+/HER2- advanced or metastatic breast cancer previously treated with endocrine-based therapy. About Arvinas Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit and connect on LinkedIn and X. Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding: the NDA review and to the first ever FDA-approved PROTAC ER degrader potentially being available to patients who could benefit from a much needed, new treatment option; and vepdegestrant's development as a potential monotherapy for ER+/HER2- advanced or metastatic breast cancer with ESR1 mutations in the second line-plus setting. All statements, other than statements of historical fact, contained in this press release, including statements regarding Arvinas' strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words 'anticipate,' 'believe,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'target,' 'goal,' 'potential,' 'will,' 'would,' 'could,' 'should,' 'look forward,' 'continue,' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Arvinas may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Arvinas makes as a result of various risks and uncertainties, including but not limited to: whether Arvinas and Pfizer will successfully perform their respective obligations under the collaboration between Arvinas and Pfizer; whether Arvinas and Pfizer will be able to successfully conduct and complete clinical development for vepdegestrant as a monotherapy; whether the VERITAC-2 clinical trial will meet the secondary endpoint for overall survival; risks related to our expectations regarding the potential clinical benefit of vepdegestrant to patients; uncertainties relating to regulatory applications and related filing and approval timelines, including the New Drug Application seeking FDA approval of vepdegestrant and the risk that any regulatory approvals, if granted, may be subject to significant limitations on use or subject to withdrawal or other adverse actions by the applicable regulatory authority; whether FDA or other regulatory authorities will require additional information or further studies, or may fail or refuse to approve or may delay approval of vepdegestrant; whether Arvinas and Pfizer, as appropriate, will be able to obtain marketing approval for and commercialize vepdegestrant and other product candidates on current timelines or at all; Arvinas' ability to protect its intellectual property portfolio; Arvinas' reliance on third parties; whether Arvinas will be able to raise capital when needed; whether Arvinas' cash and cash equivalent resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; and other important factors discussed in the 'Risk Factors' section of Arvinas' Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent other reports on file with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Arvinas' current views with respect to future events, and Arvinas assumes no obligation to update any forward-looking statements, except as required by applicable law. These forward-looking statements should not be relied upon as representing Arvinas' views as of any date subsequent to the date of this release. Contacts Investors: Jeff Boyle +1 (347) 247-5089 [email protected] Media: Kirsten Owens +1 (203) 584-0307 [email protected]
CNN
17 minutes ago
- CNN
Trump's attacks on international student enrollment could ultimately shake the economy
The Trump administration's statements and actions aimed at curtailing the number of international students in the US have sent a chill of uncertainty through higher education institutions. These American schools have become more reliant on the higher tuition paid by international students as state and federal support has waned. Now, their financial viability could be shaken. That could have a negative impact on US-born students seeking a college education, and economists and researchers warn that the ripple effects could extend well beyond the lawns of college campuses: A drop-off in international students could reverberate through the US labor market and broader economy in years to come. 'The skill premium, as we call it, is very large, which is why highly educated workers earn so much more,' said Michael Lovenheim, a labor economist and professor at Cornell University's School of Industrial and Labor Relations. International students, he added, 'generate not only returns to themselves through higher wages, but they work in sectors that generate economic growth, they start businesses, they work in high-growth areas that generate more productivity and increase [Gross Domestic Product].' And that economic impact, he said, is 'positive and large.' During the 2023-24 academic year, 1.1 million international students were credited with supporting 378,175 jobs, half of which were at colleges and universities and the rest being in other sectors such as housing, food service, retail, transportation and insurance, according to NAFSA: Association of International Educators. All told, that amounted to a record-high economic contribution of $43.8 billion, according to the member-based organization. Reducing enrollment or hurting international students' desire to study in America, he added, will 'lessen our economic competitiveness in the medium run and maybe the long run as well, depending on how things play out.' The Trump administration's efforts to limit international students have already affected the Global Migration Center, an interdisciplinary research center at the University of California, Davis, said center director Giovanni Peri, an economist and UC-Davis professor who has researched the economic impacts of international migration. 'The new cohort of students that are coming (from other countries), we've already lost a few of them because of the uncertainty of the funding and the visa that we're providing,' Peri told CNN in an interview. 'A couple of people who were from Europe decided to go to England.' And the international students currently conducting research at the center are experiencing hardships as well, he added. 'They are really struggling with their funding; they are not traveling internationally. A couple of my students could not go to international conferences in the last couple of months because they were worried they would not have been able to come back' because of worries they'd get stopped at the border, Peri said. The research itself, he added, has become harder with reduced funding. 'It took a long time for the US to establish itself as, by far, the strongest university environment in the world,' he said. 'But things change, and things can change in a more permanent way.' If international students elect to instead study in Canada, Europe, Australia or other regions, that loss will ultimately damage the US economy, he said. 'The rate at which foreign students create firms in the United States after graduation is about four times as large as the rate at which Americans create,' Peri said, citing his research on the topic. 'So, there will be fewer companies created. There will be fewer scientists and engineers to fill other companies in the US; there will be less growth of companies, jobs, and lower income in many local economies.' The potential business generation effect already is hampered by immigration restrictions or challenges, Peri noted. In an earlier study, he and his colleagues found that because of immigration and visa restrictions, only 20% of international US Master's graduates remained in the US and worked for at least two years. There have been legislative proposals to give a green card to students who earn a degree in the US (a policy that Trump publicly supported), Peri said, adding that 'not only this has not happened, but we have made several steps in the opposite direction.' 'This is now a completely different world, but this idea of students who study in the US should be able, if the company makes an offer, to have a visa had such a consensus that was so broad and so bipartisan,' he said. 'Because everybody saw that the US helped these students and this human capital to be created and that some of the benefits could stay in the US if there is an option.' If the Trump administration's policies and approach toward international students don't change significantly, these negative consequences could be felt in the broader US economy in two to three years, he added. Not excusing the 'brutality' of the Trump administration's approach, recent events could drive a meaningful debate around the internationalization of the American student body, David Bell, a history professor at Princeton, wrote Tuesday in a New York Times opinion piece. Bell noted that 1.1 million international students enrolled in the 2023-2024 school year — four times the enrollment 45 years ago. 'Like many large social changes, this one happened without much conscious planning or debate,' he wrote. 'Foreign students kept applying in ever greater numbers, and universities happily admitted them, since non-Americans receive merit- and need-based financial assistance at much lower rates than Americans do. It has taken Donald Trump's crude and vengeful swipe at Harvard to draw much attention to the subject.' In a follow-up interview with CNN, Bell noted the potential trade-offs with expanding international enrollment: On one hand, universities can serve as engines for future economic growth and further global relationships; on the other hand, universities potentially could fall short when serving homegrown applicants. 'The past couple of decades, the trend has been very, very strongly toward a steady increase in the number of international students, and I think it may be worth asking whether we should be continuing with that increase, or should we keep (enrollment) at the current level or even decrease the level of international students slightly,' Bell said. 'Not doing anything precipitous, not doing anything brutal as the administration seems to be attempting to do, but simply keeping an eye on the situation and recognizing the trade-offs.'
